Capsida Biotherapeutics has paused a gene therapy trial after the first patient died. | Capsida Biotherapeutics has paused a ...

The first participant in an investigational gene therapy trial of STXBP1 encephalopathy died, Capsida Biotherapeutics said.

Base editors can correct disease-causing genetic variants. After a neonate had received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency, a disease with an estimated 50% mortality in ...

A gene called SDR42E1 has been identified as a key player in how our bodies absorb and process vitamin D. Researchers found that disabling this gene in colorectal cancer cells not only crippled their ...

UC Davis researcher Dr. Hiromi Tajima explains how CRISPR-edited wheat boosts natural apigenin to promote nitrogen fixation, ...